BARD1 antibody (N-Term)

Catalog No. ABIN950603

Product Details anti-BARD1 Antibody

Target: BARD1 (BRCA1 Associated RING Domain 1 (BARD1))

Binding Specificity: AA 104-135, N-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This BARD1 antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificity: This antibody reacts to BARD1.

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Affinity chromatography on Protein A

Immunogen: KLH conjugated synthetic peptide between 104-135 amino acids from the N-terminal region of human BARD1.

Isotype: Ig Fraction

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) sodium azide as preservative

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for BARD1

Target: BARD1 (BRCA1 Associated RING Domain 1 (BARD1))

Alternative Name: BARD1 (BARD1 Products)

Synonyms: BARD1 antibody, LOC100147913 antibody, ENSMUSG00000060893 antibody, ENSMUSG00000073653 antibody, BRCA1 associated RING domain 1 antibody, BARD1 antibody, bard1 antibody, Bard1 antibody

Background: BARD1 is a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer.Synonyms: BARD-1, BRCA1-associated RING domain protein 1

Gene ID: 580

NCBI Accession: NP_000456

Pathways: DNA Damage Repair